SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Level 5 - mechanism / opinion, no new human data
In vitro mechanistic laboratory study without direct human clinical outcome data.
PubMed 32142651 · doi:10.1016/j.cell.2020.02.052
What was done
In vitro laboratory assays evaluated the host cell factors mediating SARS-CoV-2 infection. The study investigated whether SARS-CoV-2 spike (S) protein relies on the receptor ACE2 for entry and the host serine protease TMPRSS2 for priming. Researchers also tested whether a clinically approved TMPRSS2 inhibitor blocks cell entry and examined whether convalescent sera from SARS patients cross-neutralizes SARS-CoV-2 S-driven entry.
What was found
The abstract reports purely qualitative outcomes without numeric data or effect sizes: - SARS-CoV-2 utilizes ACE2 for host cell entry. - TMPRSS2 is required for SARS-CoV-2 S protein priming. - A clinically approved TMPRSS2 inhibitor blocked viral entry in vitro. - Convalescent sera from SARS patients cross-neutralized entry driven by the SARS-CoV-2 S protein.
Why it matters
This study identified the primary molecular mechanism of SARS-CoV-2 entry into host cells, establishing commonalities with SARS-CoV and highlighting TMPRSS2 inhibition as a candidate target for antiviral intervention.
Limits
The study is entirely preclinical and in vitro, meaning findings cannot establish clinical efficacy or safety in living human patients. The abstract provides no quantitative measurements (such as inhibition percentages, binding affinities, or neutralization titers) and does not specify sample sizes for the convalescent sera or cell line replicates.
Cited by
- supports SARS-CoV-2 uses ACE2 as its entry point to infect cells.